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The Biosynthesis of Capuramycin-type Antibiotics
IDENTIFICATION OF THE A-102395 BIOSYNTHETIC GENE CLUSTER, MECHANISM OF
SELF-RESISTANCE, AND FORMATION OF URIDINE-5-CARBOXAMIDE*□S
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Background: Several nucleoside antibiotics contain a uridine-5-carboxamide core of unclear origin.
Results: The A-102395 biosynthetic gene cluster was cloned, a genetic system was developed, and three enzymes were charac-
terized in vivo and in vitro.
Conclusion: Uridine-5-carboxamide originates from UMP and L-Thr by sequential reactions catalyzed by a dioxygenase and
transaldolase.
Significance: The results provide the first opportunity to methodically interrogate the biosynthesis of these unusual antibiotics.
A-500359s, A-503083s, and A-102395 are capuramycin-type
nucleoside antibiotics that were discovered using a screen to
identify inhibitors of bacterial translocase I, an essential enzyme
in peptidoglycan cell wall biosynthesis. Like the parent capura-
mycin, A-500359s and A-503083s consist of three structural
components: a uridine-5-carboxamide (CarU), a rare unsatu-
rated hexuronic acid, and an aminocaprolactam, the last of
which is substituted by an unusual arylamine-containing
polyamide in A-102395. The biosynthetic gene clusters for A-
500359s and A-503083s have been reported, and two genes
encoding a putative non-heme Fe(II)-dependent -keto-
glutarate:UMP dioxygenase and an L-Thr:uridine-5-aldehyde
transaldolase were uncovered, suggesting that C–C bond forma-
tion during assembly of the high carbon (C6) sugar backbone of
CarU proceeds from the precursors UMP and L-Thr to form
5-C-glycyluridine (C7) as a biosynthetic intermediate. Here,
isotopic enrichment studies with the producer of A-503083s
were used to indeed establish L-Thr as the direct source of the
carboxamide of CarU. With this knowledge, the A-102395 gene
cluster was subsequently cloned and characterized. A genetic
system in the A-102395-producing strain was developed, per-
mitting the inactivation of several genes, including those encod-
ing the dioxygenase (cpr19) and transaldolase (cpr25), which
abolished the production of A-102395, thus confirming their
role in biosynthesis. Heterologous production of recombinant
Cpr19 and CapK, the transaldolase homolog involved in
A-503083 biosynthesis, confirmed their expected function.
Finally, a phosphotransferase (Cpr17) conferring self-resistance
was functionally characterized. The results provide the oppor-
tunity to use comparative genomics along with in vivo and in
vitro approaches to probe the biosynthetic mechanism of these
intriguing structures.
Capuramycin-type antibiotics include A-500359s from
Streptomyces griseus SANK 60196 (1– 4), A-503083s from
Streptomyces sp. SANK 62799 (5), and A-102395 from Amyco-
latopsis sp. SANK 60206 (6). They were discovered using an
activity-based screen to identify inhibitors of bacterial phos-
pho-N-acetylmuramyl-pentapeptide translocase 1 (TL12; an-
notated as MraY), a potential, clinically unexploited antibiotic
target that initiates the lipid cycle of peptidoglycan cell wall
biosynthesis and is essential for bacterial survival (7, 8). Studies
into the biological activity of A-500359 A, the major congener
isolated from S. griseus SANK 60196, and several semisynthetic
analogues have revealed a potential utility of these natural
products as anti-tuberculosis antibiotics (9, 10). For example,
SQ641 and SQ922, two leads under preclinical development by
Sequella (Rockville, MD), have been shown to have several clin-
ically desirable attributes, including in vitro activity against
multiple-drug-resistant strains of Mycobacterium tuberculosis
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Health, NIAID, Grant AI087849 (to S. V. L.). This work was also supported by
National Center for Advancing Translational Sciences Grant UL1TR000117,
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(the primary causative agent of tuberculosis); high efficacy in a
murine model of tuberculosis; rapid kill time in vitro and in
vivo; and no toxicity to mice (11–17). Given the widespread
documentation of extensively drug-resistant M. tuberculosis
and the recent reality of totally drug-resistant M. tuberculosis
(18), the development of drugs with novel targets, such as the
capuramycin-type antibiotics, makes them attractive leads for
tuberculosis chemotherapy (19, 20).
The namesake capuramycin, initially discovered in 1986
from an antibacterial screening program (21), consists of three
structurally distinct, modular components: a uridine-5-car-
boxamide (CarU), an unsaturated -D-mannopyranuronate,
and an L--amino--caprolactam (L-ACL) (Fig. 1A) (22). Struc-
tural elucidation of the A-500359s revealed that A-500359 B 1a
(IC50  18 nM against TL1) is identical to the original capura-
mycin, and A-500359 A 1b contains a 6-C-methylated L-ACL,
a modification that has no effect on TL1 inhibition (IC50  17
nM) (1, 2). Two additional structural variants of note include the
deaminocaprolactam (de-ACL) congeners that contain a free
carboxylic acid (A-500359 F, 1c) or a methyl ester (A-500359 E,
1d), the former of which has a significantly decreased TL1
inhibitory activity (IC50  1.1 M), whereas the latter has a
slight decrease (IC50  27 nM) (3). The A-503083s 2a-2d have
structures identical to those of A-500359s with one exception;
in all cases, CarU is modified with a 2-O-carbamoyl group that
has minimal effect on TL1 inhibition and antibacterial activity
(5). A-102395 3 significantly diverges from the other capura-
mycins in both structure, wherein the L-ACL is substituted with
an unusual arylamine-containing polyamide, and activity, with
3 being the most potent inhibitor of TL1 (IC50  11 nM) yet
completely inactive against Mycobacteria sp. and other bacte-
rial strains (6).
Shortly after the rediscovery of capuramycin, the biosynthe-
sis of each component was interrogated using feeding experi-
ments with the producing strain of 1 (4). As expected, high
incorporation was observed for L-ACL using L-[1-13C]Lys (16-
fold enrichment of C-1); -D-mannopyranuronate using D-[1-
13C]mannose (11-fold enrichment of C-1); and CarU using
D-[1-13C]ribose (17-fold enrichment of C-1) (Fig. 1B). The
metabolic origin of the 5-carboxamide of CarU was less clear,
although a modest 3-fold enrichment of C-6 using [3-13C]py-
ruvate led to a proposal that the biosynthesis involves an aldol
reaction between phosphoenolpyruvate and uridine-5-alde-
hyde (UA). This mechanism of ribose chain extension is analo-
gous to that previously proposed for the biosynthesis of
polyoxin and nikkomycin, two nucleoside antibiotics that also
contain a high carbon sugar albeit with distinct chemical fea-
tures (23). However, the specific enzymatic transformations
required for the assembly of the high carbon sugar nucleoside of
either the capuramycins or polyoxin and nikkomycin have not
been biochemically established.
The biosynthetic gene cluster for 1 and 2 have been identi-
fied, and evidence for the involvement of 21 open reading
frames (ORFs) was provided by gene expression profiling of the
wild-type, 1-producing strain and several null mutants created
by random chemical mutagenesis (24, 25). Additional evidence
that the correct gene cluster was identified was provided by
functional assignment of genes involved in 2 biosynthesis: one
(capP) encoding an ATP-dependent phosphotransferase that
modifies the 3-OH of the unsaturated -D-mannopyranuro-
nate as a mechanism of self-resistance (26) and the other
(capW) encoding an L-ACL:2d transacylase (25). Bioinformatic
analysis of the gene clusters unexpectedly revealed two shared
ORFs encoding putative proteins with sequence similarity to
LipL: a non-heme Fe(II)-dependent -ketoglutarate (KG):uri-
dine-5-monophosphate (UMP) dioxygenase (27) and LipK, a
pyridoxal-5-phosphate-dependent L-Thr:UA transaldolase (28).
These two enzymes sequentially convert UMP to (5S,6S)-5-
C-glycyluridine (GlyU) during the biosynthesis of A-90289, a
FIGURE 1. Structure and biosynthesis of representative capuramycin-
type inhibitors of TL1. A, the CarU and -D-mannopyranuronate compo-
nents are found in all capuramycin-type antibiotics. SQ641 and SQ922 are
semisynthetic leads prepared from 2b and 1c, respectively. B, prior results
from isotopic enrichment studies using the indicated 13C-labeled precursors.
The numerical value represents the -fold enrichment at the indicated site
relative to a reference carbon.
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member of a distinct group of TL1 inhibitors that contain a
GlyU component in the final product (Fig. 2) (29,
30). Additional members of the GlyU-containing nucleoside
antibiotics with identified biosynthetic gene clusters include
liposidomycins (31), caprazamycins (32), muraymycin (33),
muraminomicin (34), and the recently discovered sphaer-
imicins (35). Thus, the uncovering of these two genes within the
clusters for 1 and 2 suggested that the biosynthesis of CarU
proceeds via condensation of L-Thr with UA to generate GlyU
as a cryptic pathway intermediate. Herein we provide evidence
through newly designed feeding experiments that this is indeed
the case. The probability for the involvement of an L-Thr:
UA transaldolase in CarU biosynthesis was subsequently
exploited to clone and characterize the 3 gene cluster. The first
genetic system for a producer of the capuramycin-type antibi-
otics was developed using the 3-producing strain, which, in
addition to in vitro characterization of enzymes with sequence
similarity to CapP (Cpr17), LipL (Cpr19), and LipK (CapH), has
provided new insight into the resistance and biosynthetic strat-
egies for the capuramycin-type antibiotics.
Experimental Procedures
Standards—UA and GlyU were prepared following previ-
ously described procedures (27, 28). 2a and 2c were isolated
from Streptomyces sp. SANK 62799, and 3 was isolated from
Amycolatopsis sp. SANK 60206 following the procedures
described (5, 6). Mass, 1H, and 13C NMR spectroscopic analyses
of 3 were identical with the prior report (Fig. 3).
Isotopic Enrichment—Fermentation media and growth con-
ditions for Streptomyces sp. SANK 62799 were as described
previously (5). A seed culture was incubated at 28 °C for 48 h,
when 1.5 ml was used to inoculate fresh media (50 ml of liquid
medium in a 250-ml flask). After fermentation for 70 h, 25 mg of
filter-sterilized [1-13C]Gly, [2-13C]Gly, or L-[13C4,15N]Thr was
FIGURE 2. Structure and biosynthesis of A-90289, a GlyU-containing nucleoside antibiotic. The pathway starts with UMP that is converted to GlyU by the
sequential reactions catalyzed by LipL and LipK.
FIGURE 3. 1H and 13C NMR spectra of 3 in methanol-d4.
Biosynthesis of Capuramycin-type Antibiotics
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added to each flask. Fermentation was continued an additional
72 h. An equal volume of methanol was added directly to the
culture and mixed vigorously prior to centrifugation to remove
cell debris. The supernatant was lyophilized, and the dried pow-
der was resuspended in water (100 mg/ml) for HPLC purifica-
tion using a C-18 reverse phase semipreparative column. A
series of linear gradients was developed from A (0.1% TFA, 2.5%
acetonitrile) to B (0.1% TFA, 90% acetonitrile) in the following
manner (beginning time and ending time with linear increase to
percentage of B): 0 – 6 min, 0% B; 6 –26 min, 100% B; 26 –30
min, 100% B; 30 –34 min, 0% B; and 34 –35 min, 0% B. The flow
rate was kept constant at 3.5 ml/min, and elution was moni-
tored at 260 nm. Purified 2a and 2c were analyzed by NMR, and
relative peak intensities were assigned based on C-2 and C-3
from the natural abundance 13C NMR spectra.
Cloning of the 3 Gene Cluster—Amycolatopsis sp. SANK
60206 genomic DNA was partially digested with Sau3AI to give
40-kb DNA fragments that were dephosphorylated with bac-
terial alkaline phosphatase and ligated into BamHI-digested
cosmid vector SuperCos1 (Stratagene, Cedar Creek, TX),
which was dephosphorylated by bacterial alkaline phosphatase
after XbaI digestion. The ligation products were packaged with
Gigapack III Gold packaging extract as described by the manu-
facturer (Stratagene), and the resulting recombinant phage was
used to transfect Escherichia coli XL-1 Blue MR. Approxi-
mately 8,000 colonies from the obtained genomic library were
screened by colony hybridization using a digoxigenin-labeled
lipK/capH homologous DNA fragment obtained by PCR using
degenerate primers (supplemental Table 1) and genomic DNA
from Amycolatopsis sp. SANK 60206. Hybridization was car-
ried out using DIG Easy Hyb (Roche Applied Science) at 42 °C,
and the resulting filter was washed under high stringency con-
ditions (0.1 SSC including 0.1% SDS, 68 °C). Detection was
performed using CDP-Star (Roche Applied Science) according
to the manufacturer’s procedures.
Based on restriction digest analysis, three positive cos-
mids, pNCap01, pNCap02, and pNCap03, were isolated and
sequenced using a Roche Applied Science GS FLX system
(Operon Biotechnologies). The terminal region of pNCap03
was used as a probe to identify a 10-kb DNA fragment following
BamHI digestion of genomic DNA, which was cloned into
pUC19 to yield pUC/B10k. This insert was subsequently used as
a probe to rescreen the library to identify a fourth cosmid,
pNCap04, which was also sequenced to complete the genetic
locus. Potential open reading frames were defined using Frame-
plot version 4.0, and database comparison for sequence homology
was performed with BLAST search tools using the National Cen-
ter for Biotechnology Information (Bethesda, MD).
Gene Inactivation and Production Analysis—Genes were in-
activated using REDIRECT technology (36). In short, pNCap03
was introduced into E. coli BW25141/pKD78, and the linear
PCR fragment obtained with template pIJ773 was introduced
by electroporation. Following confirmation of the genotype
using PCR, the modified cosmids were introduced into
Amycolatopsis sp. SANK 60206 by conjugation using E. coli
ET12567(pUZ8002). Apramycin resistance was used to select
for a double-crossover event, the genotype of which was subse-
quently confirmed by both PCR and Southern blot analysis.
For comparative analysis of 3 production in the wild-type
and mutant strains, 2 liters of culture broth was centrifuged at
2,600  g for 20 min to remove mycelia. The pH of the super-
natant was adjusted to 3.0 with concentrated HCl followed by
the addition of an equal volume of methanol. After vigorous
mixing for 1 h, the insoluble material was removed by centrifu-
gation (6,000  g for 40 min), and the solvent from the recov-
ered supernatant was removed by rotary evaporation and
lyophilization. Dried bacterial extracts (250 – 400 mg) were dis-
solved in 1.6 ml of 1:1 water/methanol, and the pH was adjusted
to 3– 4 with concentrated HCl if necessary prior to the addition
of 6.4 ml of cold acetonitrile. The resulting mixture was vor-
texed for 5 min, followed by sonication for 1 min, and the insol-
uble material was removed by centrifugation (2,600  g for 10
min). The supernatant was recovered and dried under a stream
of nitrogen. The dried sample was resuspended in 50 l of
methanol for analysis by LC-MS-MS.
LC-MS-MS analysis of 3 was carried out using a Shimadzu
UFLC equipped with an Apollo C18 column (250  4.6 mm, 5
m) coupled to an AB Sciex 4000-Qtrap hybrid linear ion trap
triple quadrupole mass spectrometer in multiple-reaction-
monitoring mode. The mobile phase consisted of 10 mM
ammonium formate with 0.1% formic acid in water (A) and
0.1% formic acid in acetonitrile (B). A series of linear gradients
was developed from A to B in the following manner (beginning
time and ending time with linear increase to percentage of B): 0
min, 2% B; 0 – 8 min, 2% B; 8 –27 min, 90% B; 27–30 min, 90% B;
and 30 –32 min, 2% B. The flow rate was kept constant at 0.5
ml/min with a column temperature of 30 °C, and elution was
monitored at 260 nm. The mass spectrometer was operated in
the negative electrospray ionization mode with optimal ion
source settings determined with 3 standard with a declustering
potential of 135 V, entrance potential of 10 V, collision
energy of 60 V, collision cell exit potential of 7 V, curtain gas
of 20 p.s.i., ion spray voltage of 4,200 V, ion source gas 1/gas 2
of 40 p.s.i., and temperature of 550 °C. Multiple-reaction-mon-
itoring transitions monitored were as follows: 763.316/189.9
and 763.316/120. Negative electrospray ionization mode was
used to analyze samples because it was more sensitive com-
pared with positive electrospray ionization mode for 3.
Reverse Transcriptase-PCR Analysis—All procedures were
performed according to the provided protocol. A TRIzol Max
bacterial RNA isolation kit (Ambion) was used to extract total
RNA from wild-type and mutant strains. The SuperScript III
first-strand synthesis system for RT-PCR (Invitrogen) was used
to synthesize the total cDNA from total RNA. Takara Taq was
used to amplify target genes using total cDNA as template.
Characterization of Recombinant Enzymes—Procedures for
cloning of genes, heterologous production and purification of
proteins, and enzyme assays used standard protocols (26 –28).
The primers used for cloning were as follows: cpr17, 5-GGT-
ATTGAGGGTCGCATGACCGAGACCGAGATCAC-3
(forward)/5-AGAGGAGAGTTAGAGCCCTATCCGTG-
GAATCGGGCCAG-3 (reverse); cpr19, 5-GGTATTGAG-
GGTCGCATGCAGCAGCTGCAAGCCG-3 (forward)/
5-AGAGGAGAGTTAGAGCCTCAATTGGAGGCGCG-
GGG-3 (reverse); capH, 5-GGTATTGAGGGTCGCATG-
ACTGATATCAGGGAGCTCCGCAAG-3 (forward)/5-
Biosynthesis of Capuramycin-type Antibiotics
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AGAGGAGAGTTAGAGCCTCAGGAGAACTCGACGAA-
ATAGAAGGGAG-3 (reverse). DNA templates for PCR
cloning were pNCap02 for cpr17 and cpr19 and cosmid N-4 for
capH (25). The capH gene was subcloned into pUWL20pw and
expressed as described (25).
Results
GlyU Is a Biosynthetic Intermediate for CarU—An ORF
encoding a protein with high amino acid sequence similarity to
the transaldolase LipK is located within the two gene clusters
that have been identified for the CarU-containing nucleoside
antibiotics: 1 (ORF14, 55% identity/81% similarity) and 2
(CapH, 47% identity/79% similarity) (35). Similarly, an ORF
encoding a protein with moderate sequence similarity to the
dioxygenase LipL is found within the 1 and 2 gene clusters
(Table 1). Both LipK and LipL were previously biochemically
characterized to establish that C-6 and C-7 of GlyU originates
from C-2 and C-1, respectively, of L-Thr through a transaldol-
like reaction using UA as the aldol acceptor (Fig. 2) (27, 28).
LipK, the catalyst for the transaldol-like reaction, was com-
pletely inactive when L-Thr was replaced with Gly or L-Ser
despite having the closest sequence homology with proteins
annotated as serine hydroxymethyltransferases that utilize
tetrahydrofolic acid to interconvert Gly and L-Ser (28). With
this information in hand, the metabolic origin of the 5-carbox-
amide of CarU was re-investigated by undertaking feeding
experiments with isotopically enriched Gly and L-Thr using the
2-producing strain.
To initially probe the metabolic origin of the 5-carboxam-
ide, either [1-13C]Gly or [2-13C]Gly was added to the culture
both of the 2-producing strain. Under the growth conditions
employed, 2a was the major congener produced and, as pre-
dicted from the bioinformatics analysis, no significant enrich-
ment at C-6 was observed based on comparative analysis of the
13C NMR spectra (data not shown). However, a 6% enrichment
of the 3-O-methyl group was observed using [2-13C]Gly, which
is similar to incorporation results that have been reported for
other actinomycete-derived O-methylated metabolites (37). In
contrast to the Gly enrichment experiments, the de-ACL deriv-
ative 2c was the major congener produced when fed with
L-[13C4,15N]Thr. Comparative analysis of the 13C NMR spectra
of purified 2c revealed a 15% enrichment at C-6 (Fig. 4), which
is substantially greater than that previously reported with pyru-
vate (4). This high level of enrichment is comparable with the
levels observed for enrichment of L-ACL with L-Lys, which has
been supported by biochemical studies (25). Thus, the data are
consistent with direct incorporation of L-Thr via a transaldol-
like mechanism. Additionally, a 13C-15N heteronuclear spin
coupling at C-6 of the 13C-NMR spectrum (JCN  18 Hz) was
detected that, along with analysis of the LC-MS spectrum (data
not shown), is consistent with concomitant 15N incorporation
from L-Thr during the biosynthesis of CarU.
Transaldolase as a Genetic Fingerprint for Identifying the 3
Gene Cluster—After providing evidence that CarU biosynthesis
proceeds with direct incorporation of L-Thr, the probable
involvement of an L-Thr:UA transaldolase was exploited as a
genetic fingerprint to identify the biosynthetic gene cluster for
3. We have previously designed degenerate primers based on
FIGURE 4. Isotopic enrichment using L-[13C4,
15N]Thr. A, 13C NMR spectrum
of 2c obtained with L-[13C4,
15N]Thr feeding. B, 13C NMR spectrum of 2c
obtained without feeding (natural abundance 13C).
TABLE 1
Sequence comparison in percentage identity/percentage similarity among putative KG:UMP dioxygenases
a LipL is encoded within the biosynthetic gene cluster for A-90289, Cpz15 within the cluster for caprazamycin, LpmM within the cluster for liposidomycin, Mur16 within the
cluster for muraymycin, SphE within the cluster for sphaerimicin, Mra24 within the cluster for muraminomicin, ORF7 within the cluster for A-500359, CapA within the
cluster for A-503083, and Cpr19 within the cluster for A-102395.
b Mra24 appears truncated and inactive, missing 57 amino acids at the C terminus when aligned with LipL.
c GlyU, 5-C-glycyluridine-containing nucleoside antibiotics.
d CarU, uridine-5-carboxamide-containing nucleoside antibiotics.
Biosynthesis of Capuramycin-type Antibiotics
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distinctive sequence blocks found within the functionally
assigned L-Thr:UA transaldolases (35), and these primer sets
were utilized to amplify DNA fragments of the expected size
from the genomic DNA of the producing strain of 3 (Fig. 5). The
pattern and size of the PCR product were similar to those pre-
viously reported using template DNA from the producing
strains of 1 and 2, and, as expected, no PCR product was
obtained using genomic DNA isolated from Streptomyces livi-
dans TK21, whose whole genome has been sequenced and does
not harbor the homologous gene (Fig. 5).
The PCR products amplified using the genomic DNA from
the producing strain of 3 were subsequently utilized as probes
to identify three overlapping cosmids (pNCap01– 03) encom-
passing 57-kb DNA, which were sequenced and analyzed to
reveal 49 complete ORFs (Fig. 6A). One of the ORFs (cpr25)
encoded the expected L-Thr:UA transaldolase with moderate
(43–50%) to high (70 –79%) amino acid sequence identity to
transaldolases encoded in gene clusters for GlyU-containing
and CarU-containing nucleoside antibiotics, respectively. Due
to the novel chemical structure of the polyamide component of
3 and hence uncertainty regarding its mechanism of biosynthe-
sis and incorporation, the cluster was extended by first cloning
a BamHI-digested, 10-kb DNA fragment that overlapped with
pNCap03. The cloned DNA fragment was subsequently used as
a probe to identify a fourth cosmid, pNCap04. Following
sequencing and bioinformatic analysis, a total of 85 kb of
contiguous DNA was identified, including 69 complete ORFs
and an additional ORF (cpr51) in pNCap04 that has a homolog
within the 1 and 2 biosynthetic gene cluster, thus bringing the
total shared ORFs for CarU-containing nucleoside antibiotics
to 16 (Fig. 6, A and B). The closest homologs and putative func-
tions of the ORFs are listed in supplemental Table 1; ORFs
predicted to be involved in the biosynthesis of 3 were annotated
as cpr17-cpr57, for capuramycin-related nucleoside.
The genetic architecture of the clusters for 1 and 2 is virtually
identical, excluding a single ORF encoding a truncated 2-O-
carbamoyltransferase within the 1 gene cluster that leads to the
sole structural variation between these two groups of capura-
mycin-type antibiotics. Conversely, the 16 conserved ORFs
within the 3 gene cluster have a genetic organization different
from that found in 1 and 2 (Fig. 6B). Nonetheless, individual
comparison of the gene products revealed a relatively high
amino acid sequence identity, which includes the aforemen-
tioned transaldolase (Cpr 25; 79% identity with CapH) and
non-heme Fe(II)-dependent KG:UMP dioxygenase (Cpr19;
76% identity with CapA). Additional shared gene products of
note include a phosphotransferase Cpr17, probably involved in
self-resistance (53% identity with CapP), a carboxymethyltrans-
ferase (Cpr27; 57% identity with CapS), and a putative amide
bond-forming N-transacylase (Cpr51; 65% identity with
CapW). CapS and CapW have been shown to function sequen-
tially to activate the carboxylic acid of 2c in the form of the
methyl ester 2d, followed by transacylation to incorporate the
L-ACL to generate 2a (Fig. 6C). The uncovering of genes for
Cpr27 and Cpr51 suggests that the unusual arylamine-contain-
ing polyamide of 3 is incorporated using a comparable mecha-
nism (i.e. carboxylic acid 1c 3 methyl ester 1d 3 amide 1a)
(Fig. 6C), which was unexpected given the unique chemical
nature of the acyl acceptors.
Phosphorylation by Cpr17 as a Mechanism of Self-re-
sistance—Heterologous expression of cpr17 in Streptomyces
albus yielded a recombinant strain that was, in contrast to the
strain harboring the empty vector, resistant to 1a at 500 g/ml
(Fig. 7A). The cpr17 gene was subsequently cloned and
expressed in E. coli to yield soluble protein for activity assess-
ment. CapP, which was previously shown to confer resistance
by catalyzing regiospecific phosphorylation at the 3-OH of 2a
and 2d (26), was used as a control. Activity of Cpr17 was initially
assessed by HPLC using 2a, 2c, and 2d as potential substrates,
and new peaks appeared with 2a and 2d. The retention time of
the new peak was identical when Cpr17 was substituted with
CapP (Fig. 7, B and C), consistent with the formation of
3-phospho-2a and -2d, respectively. CapP utilized 2c with a
very low turnover of 0.2 min1 (26), and accordingly no
appreciable activity was detected using Cpr17 or CapP with 2c
under the reaction conditions employed here (data not shown).
The activity of Cpr17 and CapP was tested with 3, and HPLC
analysis revealed a new peak in both cases with an (M  H) ion
at m/z  843.0 (Fig. 7, D–F), consistent with the molecular
formula for 3-phospho-3 (C31H37N6O20P; expected (M  H)
ion at m/z  843.2). Although the limited availability of 3 pre-
cluded structural elucidation and product bioactivity analysis at
the current time, the results suggest that Cpr17, like CapP,
functions as capuramycin-type antibiotic phosphotransferase
involved in self-resistance.
After identifying the function of Cpr17, single-substrate
kinetic experiments were performed using 2a as a substrate.
Using nearly saturating ATP and variable 2a, standard Michae-
lis-Menten kinetics were observed, yielding a Km  146 	 13
M and kcat  5.8 	 0.2 min1 (Fig. 6G), the former constant
similar to and the latter 5-fold lower than that reported for
CapP (Table 2). Single-substrate kinetic experiments with sat-
FIGURE 5. PCR amplification of the probable L-Thr:uridine-5-aldehyde
transaldolase gene. Template genomic DNA was isolated from S. lividans
TK21 (negative control) and the producing strains of the indicated CarU-con-
taining nucleoside antibiotics. The primers were designed according to the
conserved sequence as described previously (35), and primer pairs that were
utilized are as follows: A-F1/C-R1 (a); A-F1/D-R1 (b); A-F2/C-R1 (c); A-F2/D-R1
(d); B-F1/C-R1 (e); and B-F1/D-R (f).
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urating 2a and variable ATP yielded a Km  1.4 	 0.1 mM and
kcat  10.1 	 0.4 min1 (Fig. 7G). The high observed Km for
ATP prompted us to test GTP as an alternative phosphate
donor, which served as an excellent substrate for Cpr17, yield-
ing a Km  9.2 	 1.7 M and kcat  3.3 	 0.1 min1 (Fig. 7G), a
50-fold improvement in catalytic efficiency, suggesting that
GTP is the in vivo substrate for Cpr17. A similar nucleotide
preference has been reported recently for certain aminoglyco-
side phosphotransferases (38 – 40).
Development of a Genetic System and Biochemical Interroga-
tion of CarU Biosynthesis—Unlike the producing strains for 1
and 2, which have not been amenable to genetic manipulation,
gene inactivation was possible with the 3-producing strain, thus
enabling the first in vivo analysis of the gene clusters for the
capuramycin-type antibiotics. Both cpr19 and cpr25 were indi-
vidually targeted for inactivation by double crossover homo-
logous recombination, and successful inactivation of each was
confirmed by PCR and Southern blot analysis (Fig. 8, A–C). The
resulting 
cpr19 and 
cpr25 mutant strains were unable to
produce 3 (Fig. 8D), consistent with an essential role in the
biosynthesis of 3. Gene complementation has yet to be success-
ful in this strain, and thus to exclude possible polar effects, the
expression levels of the upstream and downstream genes were
analyzed by RT-PCR. Using mRNA extracted from the 
cpr25
mutant strain at the onset of 3 production, expression of cpr25
was not detected, whereas genes flanking cpr25 were clearly
expressed (Fig. 8E). In contrast, all three genes were detected
within the wild-type strain, suggesting that there is no polar
FIGURE 6. Characterization of the 3 biosynthetic gene cluster. A, four overlapping cosmids were identified and sequenced to define the genetic organiza-
tion of the 3 biosynthetic gene cluster. The cpr25 gene encodes the putative L-Thr:uridine-5-aldehyde transaldolase that was targeted to identify the genetic
locus. B, comparative analysis of the sequenced region of chromosomal DNA from the 2- and 3-producing strains. Highlighted in blue are the minimal ORFs
predicted to be essential for 3 biosynthesis, whereas the two ORFs in black, cpr19 and cpr25, are predicted to encode for a non-heme Fe(II)-dependent KG:UMP
dioxygenase and L-Thr:uridine-5-aldehyde transaldolase, respectively. C, shared biosynthetic pathway leading to the core structure of 2 and 3 and divergence
upon amide bond formation.
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FIGURE 7. Characterization of the phosphotransferase Cpr17. A, resistance to 1a conferred to S. albus upon heterologous expression of cpr17 using variable
amounts of 1a (0 g/ml (column 1), 100 g/ml (column 2), and 500 g/ml (column 3)). The top two rows (pWHM3 (row 1) and pWHM3-ermEp-cpr17 (row 2))
consist of mycelia diluted 1:10 following homogenization of a liquid culture of S. albus, whereas the bottom two rows (pWHM3 (row 3) and pWHM3-ermEp-cpr17
(row 4)) consist of mycelia diluted 1:100 prior to spotting on ISP2 agar plates. B–D, HPLC traces with the indicated substrate incubated without enzyme (i), with
Cpr17 (ii), and with CapP (iii). , 3-phospho-2a; , 3-phospho-2d; F, 3-phospho-3. A260, absorbance at 260 nm. *, unidentified contamination peak. E, mass
spectrum of the peak at retention time 7.7 min (D, trace i) corresponding to authentic 3. F, representative mass spectrum of the peak at retention time 7.6 min
(D, trace ii or iii) corresponding to 3-phospho-3. All mass data are reported in negative ion mode. G, plots for single-substrate kinetic analysis of Cpr17.
TABLE 2
Michaelis-Menten kinetic parameters
a Data taken from Ref. 26.
b Data taken from Ref. 27.
c Data taken from Ref. 28.
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effect due to cpr25 inactivation. Ambiguous results were
obtained with expression analysis within the 
cpr19 mutant
strain, and hence we turned our attention to in vitro character-
ization for direct evidence of the involvement of cpr19 in the
biosynthesis of 3.
The gene encoding cpr19 was heterologously expressed in
E. coli to obtain pure, recombinant protein (Fig. 9A). Based on
prior characterization of LipL, Cpr19 was expected to convert
UMP to UA in a reaction that is dependent upon Fe(II), O2, and
KG. HPLC analysis of reactions with all of these components
revealed a new peak that co-eluted with authentic UA, and as
expected, the formation of the product was absolutely depen-
dent on the inclusion of O2 and KG (Fig. 9B). Inductively cou-
pled plasma MS revealed a fraction (4%) of Cpr19 co-purified
with Fe(II), thus explaining the residual activity in the absence
of additional Fe(II). Optimal activity for Cpr19 was observed
between 100 and 1000 M FeCl2 (Fig. 9C). Similar to other
enzymes of this dioxygenase superfamily, including E. coli tau-
rine dioxygenase (41), ascorbic acid enhanced the activity,
reaching an optimum between 1 and 5 mM (Fig. 9D). No tested
divalent or transition metals were able to substitute for Fe(II),
and similarly to LipL, Zn2 inhibited the reaction (Fig. 9E).
Finally, single-substrate kinetic analysis yielded a Km  25 	 4
M and kcat  95 	 10 min1 with respect to UMP and Km 
6.2 	 1.0 M and kcat  78 	 7 min1 with respect to KG (Fig.
9F) (Table 2).
The overall biochemical and kinetic properties of Cpr19
were comparable with those previously reported for LipL
excluding two of note (27). First, although LipL is able to cata-
lyze uncoupled oxidative decarboxylation of KG, the rate of
FIGURE 8. Gene inactivation in Amycolatopsis sp. SANK 60206. A, strategy utilized for gene inactivation demonstrated with cpr25. B, PCR analysis of genomic
DNA isolated from the wild type (WT; expected 1.2 kb) and 
cpr25 mutant (
; expected 1.8 kb) strains. C, Southern blot analysis of ApaI-digested genomic DNA
from WT and 
cpr25 mutant strains using the indicated probe. D, LC-MS-MS analysis of authentic 3 (i) and production from wild-type strain (ii), 
cpr19 (iii),

cpr25 (iv), and 
cpr51 (v). E, RT-PCR analysis of the indicated genes using mRNA isolated from the 
cpr25 mutant strain or wild-type strain. F, RT-PCR analysis
of the indicated genes using mRNA isolated from the 
cpr51 mutant strain or wild-type strain. M, DNA ladder.
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formation of succinate in the absence of UMP was moderately
greater for Cpr19 (kcat  1.6 min1 compared with kcat  0.4
min1), corresponding to a relative turnover of 2.5% to the
UMP-containing reaction (Fig. 9G). Second, in contrast to the
high specificity of LipL, Cpr19 catalyzed UA formation with
alternative -keto acids pyruvate and -ketoadipate. Single
substrate kinetic analysis yielded constants of Km  8.2  102 	
90 mM and kcat  9.0 	 2.0 min1 with respect to pyruvate and
Km  1.1  102 	 16 mM and kcat  17 	 6 min1 with respect
to -ketoadipate (Table 2), a relative efficiency of 8.7  104
and 1.2  102, respectively, compared to the preferred sub-
strate KG. Similarly to LipL, however, Cpr19 was inactive with
-ketobutyrate, -ketovalerate, and oxaloacetate.
After demonstrating that UA is a biosynthetic intermediate
of CarU-containing nucleosides, the probable L-Thr:UA
transaldolase, Cpr25, was targeted for characterization; how-
ever, soluble protein could not be obtained using multiple hosts
and a variety of expression conditions. Instead, Cpr25 was sub-
stituted with CapH that is encoded within the 2 biosynthetic
gene cluster (5). Similarly to LipK (28), soluble CapH was only
produced in S. lividans TK64 (Fig. 10A), and UV-visible spec-
troscopic analysis revealed trace amounts of PLP co-purified
with CapH (Fig. 10B). Enzyme assays monitored by HPLC
revealed identical traces to LipK (Fig. 10C), and the product
peak was characterized by spectroscopic analysis to demon-
strate that CapH is an L-Thr:UA transaldolase. The biochemical
properties of CapH were similar to those of LipK, and kinetic
analysis following acetaldehyde production (28) yielded kinetic
constants of Km  19 	 6 mM and kcat  44 	 5 min1 with
respect to UA and Km  25 	 8 M and kcat  32 	 2 min1
with respect to L-Thr (Fig. 10D), values comparable with those
for LipK (Table 2).
Cpr51 Is Essential for 3 Biosynthesis—To determine whether
cpr51, encoding a putative N-transacylase with a proposed
functional role comparable with that of CapW, was involved in
the biosynthesis of 3, the gene was inactivated by double-cross-
over homologous recombination, which was confirmed by PCR
and Southern blot analysis (data not shown). Utilizing mRNA
FIGURE 9. In vitro characterization of the non-heme Fe(II)-dependent KG:UMP dioxygenase Cpr19. A, SDS-PAGE of purified His6-Cpr19 (expected 35.3
kDa). The engineered N-terminal His6 tag contributes 5 kDa to the native molecular mass. B, HPLC analysis of the reaction catalyzed by Cpr19 using UMP as
the prime substrate with all components (i) or the omission of ascorbic acid (ii), ferrous iron (iii), KG (iv), or O2 (v). Similarly to LipL (27), Cpr19 co-purified with
iron (4 	 0.5%), explaining the formation of trace amounts of product without exogenous ferrous iron. F, uridine-5-aldehyde; A260, absorbance at 260 nm. C,
optimal activity of Cpr19 with respect to varied Fe(II). D, optimal activity of Cpr19 with respect to varied ascorbic acid. E, activity with the addition of Zn2 using
the optimized reaction conditions. For comparison, the activity of LipL with Zn2 is shown (from Ref. 27). F, plots for single-substrate kinetic analysis of CapH
using optimized activity conditions. G, uncoupled oxidation of -ketoglutarate to succinate in the absence of prime substrate (UMP), which for Cpr19 yielded
a kcat  1.6 min
1, corresponding to a relative turnover of 2.5% compared with the UMP-containing reaction. 14, a 14-fold increase in enzyme utilized
compared with data shown for 1 Cpr19. Error bars, S.D.
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extracted from the 
cpr51 mutant strain at the onset of 3 pro-
duction, expression of cpr51 was not detected, whereas genes
flanking cpr51 were clearly expressed (Fig. 8F). As expected, the
resulting 
cpr51 mutant strain was unable to produce 3 (Fig.
8D), consistent with an essential role in 3 biosynthesis.
Discussion
We have performed isotope enrichment experiments, iden-
tified the 3 gene cluster, characterized a phosphotransferase
involved in resistance, and characterized two biosynthetic
enzymes to support a shared biosynthetic paradigm for the
CarU-containing nucleoside antibiotics 1-3. Interestingly, the
biosynthesis of CarU occurs through the morphing of the pri-
mary metabolites UMP and L-Thr and not uridine and phos-
phoenolpyruvate as previously suggested. The pathway to CarU
proceeds through the unusual -hydroxy-L-amino acid GlyU as
an intermediate following sequential catalysis by a non-heme
Fe(II), KG:UMP dioxygenase, and an L-Thr:UA transaldolase.
The function of the dioxygenase Cpr19/LipL, the generation of
UA from the mononucleotide, is novel for enzymes of the non-
heme Fe(II), KG-dependent dioxygenases and thus mechanis-
tically intriguing (42– 45). Based on the mechanism for taurine
dioxygenase, which catalyzes the transformation of taurine to
aminoacetaldehyde and sulfite and is perhaps the best charac-
terized enzyme of the superfamily (46 – 48), Cpr19/LipL prob-
ably catalyze insertion of one atom of O2 into KG and the
other at C-5 of UMP, leading to a geminal hydroxyl-phospho-
ester intermediate. This labile intermediate is proposed to
undergo phosphate elimination to yield UA.
In addition to being mechanistically interesting, the identifi-
cation of the new activity of Cpr19/LipL has biosynthetic impli-
cations for multiple chemical entities. Not only is this dioxyge-
nase activity required to initiate the biosynthesis of the high
carbon sugar nucleosides CarU and GlyU, but it is also required
for biosynthesis of the aminoribosyl moiety found in the GlyU-
containing nucleoside antibiotics (Fig. 2) (49). During the
assembly of this unusual sugar, an L-Met:UA aminotransferase
uses the Cpr19/LipL product to form 5-amino-5-deoxyuridine.
The discovery of the dioxygenase and aminotransferase activi-
ties involved in aminoribose biosynthesis has subsequently led
to the uncovering of the biosynthetic gene cluster for jawsamy-
cin, whose structure contains a 5-amino-5-deoxyuridine (50).
Finally, a survey of the whole genomes of diverse actinomycetes
reveals a high prevalence of genes encoding proteins of the
dioxygenase superfamily within other putative natural product
biosynthetic operons, suggesting the potential for discovery of
comparable dioxygenase activities.
Following the reaction by Cpr19, the transaldolase Cpr25
generates a new -hydroxyamino acid that is ultimately con-
verted to the carboxamide functionality of CarU. Carboxam-
ides in primary metabolites are made by one of four enzymatic
processes: an ATP-dependent enzymatic process from a car-
boxylic acid using an NH3/Gln as the amine source, a hydrolytic
process, lyase chemistry, or (in the unusual case of L-Arg catab-
olism in certain microorganisms) an oxidative decarboxylation
catalyzed by a flavin-dependent L-Arg 2-monooxygenase (51).
Carboxamides are found in some secondary metabolites, such
as phenazines (52), oxytetracycline (53), AB-400 (54, 55), and
sarubicin A (56), and genetic or biochemical evidence suggests
that they are produced from the carboxylic acid by an ATP-de-
pendent process. A gene encoding a protein with similarity to
those catalyzing ATP-dependent carboxamide formation or
any alternative mechanism is not apparent within the 1–3 gene
FIGURE 10. In vitro characterization of the transaldolase CapH. A, SDS-PAGE analysis of partially purified His6-CapH (lane 2, expected molecular mass of 50.4
kDa). Lane 1, molecular mass standards from Bio-Rad; the engineered N-terminal His6-tag contributes 5 kDa to the predicted native molecular mass. B,
UV-visible spectrum of CapH isolated from S. lividans TK64. C, HPLC analysis of the reaction without enzyme (i) or with CapH (ii) or LipK (iii). F, (5S,6S)-5-C-
glycyluridine; A260, absorbance at 260 nm. D, plots for single-substrate kinetic analysis of CapH. Error bars, S.E.
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clusters. The revelation of a 13C-15N heteronuclear spin cou-
pling in the 13C NMR spectrum upon feeding labeled L-Thr
suggests that the C–N bond remains intact during CarU bio-
synthesis (57), providing additional support for a different,
potentially novel mechanism of carboxamide formation.
Because the conversion of GlyU to CarU is likely to involve
decarboxylation, hydroxylation, and/or oxidation, it is possible
that the PLP-dependent enzyme Cpr23, a second non-heme
Fe(II)-dependent dioxygenase Cpr18, and/or the putative oxi-
doreductase Cpr20 are involved.
The formation of the unsaturated -D-mannopyranuronate
that is attached to the CarU core is not obvious from bioinfor-
matics analysis, excluding the attachment of the sugar by the
glycosyltransferase, Cpr24. GDP-D-mannuronic acid, expected
to be an intermediate based on prior isotopic enrichment stud-
ies, is a building block of alginate, a major anionic polysaccha-
ride found in some strains of bacteria (58). During alginate
biosynthesis, GDP-D-mannuronic acid is formed from GDP-D-
mannose by a GDP-mannose 6-dehygrogenase, yet the two
remaining shared proteins encoded in the 1–3 gene clusters
with similarity to sugar biosynthetic enzymes are Cpr21, a puta-
tive NDP-hexose 2,3-dehydratase, and Cpr22, a putative NDP-
hexose 4-epimerase/dehydratase. Although Cpr21 and Cpr22
are very different in sequence and domain architecture from
GDP-mannose 6-dehygrogenase, it is possible that one or both
may perform this chemistry. Finally, the 4,5-unsaturation
found in alginate is a result of lyase (-elimination) chemistry
(58), yet it appears that the double bond is introduced by a
dehydratase reaction, possibly by Cpr20, -21, or -22. Finally,
Cpr29 is proposed to catalyze 3-O-methylation, a modification
that is found in all capuramycin-type antibiotics, although the
timing of methylation remains unclear. The three remaining
shared genes in the 1–3 gene cluster (cpr28, -30, and -31) are
predicted to encode three subunits of a functional carbon
monooxide dehydrogenase complex with an unclear role in
biosynthesis. The genetic system developed here should help in
defining their role along with the other aforementioned gene
products in 1c biosynthesis.
Similar to the disaccharadyl core, the arylamine-containing
polyamide moiety of 3 contains highly unusual chemical fea-
tures. The 3-(4-aminophenyl)-2,3-dihydroxypropanoic acid
component of the polyamide is predicted to be assembled from
chorismic acid and malonyl-CoA by minimally eight ORFs,
cpr12 and cpr32– cpr38 (Fig. 11). The pathway initially pro-
ceeds by the conversion of chorismic acid to p-aminobenzoic
acid, a transformation that occurs during the de novo synthesis
of essential folates in plants, fungi, and bacteria and requires
three enzyme activities: an L-Gln amidotransferase, a 4-amino-
4-deoxychorismate (ADC) synthase, and ADC lyase (59). In
E. coli, these three activities, which have been biochemically
confirmed, are found on proteins encoded by three distinct
genes (pabA, pabB, and pabC, respectively) located at remote
locations within the chromosome. A survey of 100 Streptomy-
ces genomes revealed that pabB and pabC are located in a con-
served, probable three-gene operon (the third gene encodes a
protein with sequence similarity to acetyltransferases of the
GNAT family), and pabA is located elsewhere within the chro-
mosome. Twenty of these 100 genomes contain at least one
additional gene encoding a PabB but, contrastingly, as part of a
bidomain protein containing an N-terminal PabA domain.
Although not yet biochemically confirmed, a protein with iden-
tical bidomain architecture has been uncovered for the biosyn-
thesis of amicetin (60), pristinamycin (61), aureothin (62), can-
dicidin/FR-008 (63), chloramphenicol (64 – 66), the recently
identified albicidin (67), and now 3. Thus, cpr38 encoding this
bidomain protein is proposed to catalyze a two-step reaction
involving amidohydrolysis of L-Gln with ammonia channeled
and incorporated into chorismic acid to generate ADC. Cpr12,
encoded by a gene that was initially believed to be outside the
gene cluster, has similarity to proteins annotated as ADC lyase
or aminotransferase class IV, of which ADC lyase belongs (59),
suggesting that this protein catalyzes the elimination of pyru-
vate to form PABA.
The remaining steps require C–C bond formation between
the carboxylic acid of PABA and a C-2 extender unit. This is
putatively initiated by Cpr37-catalyzed activation of PABA as
the acyl-adenylate with loading to the free-standing carrier pro-
tein Cpr36 to form the thioester-linked PABA. Homologous
genes are found within the actinomycin gene cluster (68),
wherein biosynthesis is proposed to be initiated by activation
FIGURE 11. Proposed biosynthetic pathway of the unique arylamine-containing polyamide of 3.
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and loading of a 4-methyl-3-hydroxyanthranilic acid starter
unit to a free-standing carrier protein. Adjacent to cpr36 are
two genes encoding proteins with similarity to a ketosynthase
and chain length factor (Cpr34 and Cpr35, respectively) that
work in concert to catalyze decarboxylative condensation
between a malonyl-S-acyl carrier protein (ACP) and recipient
thioester during aromatic polyketide biosynthesis catalyzed by
type II polyketide synthases (69). In several instances, type II
polyketide synthase systems recruit fatty acid biosynthetic
machinery during polyketide assembly, and it is probably the
same scenario here, wherein an ACP and malonyl-CoA:ACP
transacylase from fatty acid biosynthesis generate the co-sub-
strate for decarboxylative condensation by the Cpr34/35 het-
erodimer. A comparable mechanism of condensation has pre-
viously been proposed during hygromycin B biosynthesis upon
identification of its gene cluster (70).
Following formation of the -ketothioester, a putative
3-oxoacyl-ACP reductase, Cpr33, catalyzes reduction to the
-hydroxythioester intermediate, and the luciferase-like mon-
oxygenase, Cpr32, catalyzes -hydroxylation to give 3-(4-
aminophenyl)-2,3-dihydroxypropanoic acid. These last two
enzymatic steps to generate the vicinal diol of 3-(4-aminophe-
nyl)-2,3-dihydroxypropanoic acid are of particular interest
because the stereochemistry in 3 has not been established.
Sequence analysis of Cpr33 suggests the closest similarity to
3-oxoacyl-ACP reductase (FabG) from bacterial type II fatty
acid synthases, which catalyze hydride addition to the si face to
generate the R configuration (71). It is thus reasonable to
assume the same relative orientation of acyl-ACP binding and
reduction, in this case hydride addition to the re face to gener-
ate the S configuration (the PABA starter unit changes priori-
ties of the carbonyl carbon; Fig. 11). Stereoselective reduction
of other members of the short chain dehydrogenase family, to
which 3-oxoacyl-ACP reductases belong, has been the subject
of several studies, culminating in sequence signatures to predict
the stereochemical outcome, which is consistent with that pro-
posed for Cpr33 (72, 73). Introduction of the C-2 hydroxyl is
probably catalyzed by Cpr32 that has sequence similarity to
proteins annotated as FMN-dependent monooxygenases of the
bacterial luciferase family, which includes a variety of FMN- or
coenzyme F420-dependent oxidoreductases that act on struc-
turally diverse substrates. It is not possible to predict the stereo-
chemistry of -hydroxylation based solely on this information,
but assuming that catalysis does not involve epimerization at
C-3, C-2 hydroxylation leads to a change in substituent priority
at C-3 so that the ultimate product is proposed to have the 3R
configuration.
The remaining steps in polyamide biosynthesis involve for-
mation of two amide bonds, and as expected, there are putative
proteins encoded within ORFs cpr47– cpr57 that are associated
with amide bond-forming events, including an adenylation-like
domain protein with predicted specificity to a hydrophilic
amino acid (Cpr54), two carrier proteins (Cpr48 and Cpr55), a
condensation domain protein (Cpr47), and three transglutami-
nase-like proteins (Cpr49, Cpr50, and Cpr57). Based on the
functional assignment of an unrelated transglutaminase-like
protein as a condensation catalyst that uses two substrate thio-
esters during andrimid biosynthesis (74), the putative transglu-
taminases, all of which have similarity to uncharacterized MitI
in the mitomycin C gene cluster (75), potentially catalyze amide
bond formation. It is likely that this component is derived from
a Gly and L-Asp (or L-Asn) unit, although a detailed proposal for
polyamide biosynthesis at this stage would be highly speculative
without isotopic enrichment or genetic evidence. Finally, com-
ponents of Cpr41–Cpr46 have similarity to a pyruvate dehydro-
genase complex or acetolactate synthase, and their role in 3
biosynthesis, if any, is unclear, but possibly they are utilized for
pyruvate and by-product recycling that is generated by Cpr12.
The proposed final step in 3 biosynthesis is the coupling of
the arylamine-containing polyamide to the capuramycin core
via amide bond formation. Of the aforementioned natural
products containing PABA, only the aromatic amine of PABA
from amecitin is modified to an amide as also observed in 3. In
the case of amicetin, gene inactivation of aviN encoding a puta-
tive malonyl-CoA:ACP transacylase revealed it as the catalyst
for amide bond formation (60). Contrastingly, the formation of
amide bond for 2a is orchestrated by an unconventional mech-
anism featuring sequential catalysis by CapS and CapW (25).
Despite the stark structural contrast of the amine acceptor (ali-
phatic amine of aminocaprolactam versus the arylamine of the
polyamide), genes encoding putative CapS and CapW homo-
logues (cpr27 and cpr51, respectively) were identified in the 3
gene cluster, and gene inactivation demonstrated that cpr51 is
essential for 3 biosynthesis. Although no pathway intermedi-
ates could be identified, Cpr51 is proposed to catalyze the cou-
pling reaction, and future studies will be aimed at defining the
function of Cpr51 and its role and catalytic properties relative
to CapW.
In summary, we have established that UMP and, unexpect-
edly, L-Thr serve as the metabolic precursors of the CarU nucle-
oside found in the capuramycin-type antibiotics. Using this
information, the biosynthetic gene cluster for 3 was identified
to enable a thorough, comparative genomic approach to pro-
pose a biosynthetic pathway for the capuramycin-type antibi-
otics. A mechanism of self-resistance to 3 was also defined, and
the phosphotransferase Cpr17 conferring this resistance was
shown to prefer GTP as the phosphate donor. Finally, the first
genetic system for the capuramycin-type antibiotic producers
was developed, a critical advancement for interrogating the bio-
synthesis of the unusual chemical components of this family of
antibiotics.
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